Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.52

+0.2%

3:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (34787)	6/3/2010 4:47:04 PM
From: Biomaven	1 Recommendation Read Replies (2) of 52153

The Businesswire PR has the other two graphs: businesswire.com It should be noted that the reversal effect seems to decline over time until it is restored by the second infusion. The reason for this according to the company is that the LMWH was given via a subcutaneous injection, unlike unfractionated heparin which is given by infusion. The Polymedix drug reverses any currently circulating LMWH, but then any excess drug is cleared and more LMWH enters the circulation from the depot under the skin. Hence the potential need for a second infusion of drug if the acute bleeding wasn't halted. Bottom line is that reversal of LMWH is not quite as easy as for unfractionated heparin, but if the safety holds up it looks like like it would be relatively easily accomplished with the Polymedix drug. Either a longer infusion or multiple doses would be needed if bleeding didn't stop immediately. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next